Cover Image

HER2 BAJO ¿HA IMPACTADO LA CONDUCTA EN ENFERMEDAD HER2 POSITIVO?

Fuente: Redalyc

Saved in:

Bibliographic Details
Format:	Artículo científico
Language:	es
Published:	Sociedad Venezolana de Oncología 2025
Subjects:	Medicina
Online Access:	Acceder al recurso 1 Acceder al recurso 2 Acceder al recurso 3 Acceder al recurso 4 Acceder al recurso 5
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

HER2 BAJO ¿HA IMPACTADO LA CONDUCTA EN ENFERMEDAD HER2 POSITIVO?
by: ANA CECILIA CONTRERAS CASTILLO
Published: (2025)

EVITANDO LA LINFADENECTOMÍA AXILAR EN CÁNCER DE MAMA N+ TRIPLE NEGATIVO, HER2-POSITIVO TRAS QUIMIOTERAPIA NEOADYUVANTE
by: GIOVANNI VENTO
Published: (2025)

FACTORES ASOCIADOS A CÁNCER DE MAMA HER2 POSITIVO: ANÁLISIS RETROSPECTIVO DE UN HOSPITAL EN PERÚ
by: ALEJANDRA MARTÍNEZ
Published: (2022)

HER-2/NEU. BIOMARCADORES EN CÁNCER DE PRÓSTATA Y MAMA
by: I. Monet N. Sayegh
Published: (2009)

Factores clinicopatológicos asociados a la amplificación del gen HER2/neu en pacientes con cáncer de mama HER2 2+
by: Rosa América Meléndez Guevara
Published: (2017)

Características patológicas asociadas al carcinoma de mama HER-2 positivo
by: Carlos González-Müller
Published: (2005)

The evolution and prognostic impact of HER2‐low, HER2‐ultralow, and HER2‐null status in HER2‐negative early breast cancer: A pre– to post–neoadjuvant chemotherapy study
by: Yibin Qiu, et al.
Published: (2026)

Distinct Clinicopathological Features of HER2 ‐Negative, HER2 ‐Low, and HER2 ‐Overexpressing Urothelial Carcinoma in a Large Chinese Cohort
by: Shanshan Wang, et al.
Published: (2025)

p95HER2 expression in HER2‐positive breast cancer with primary resistance
by: Chih Wan Goh, et al.
Published: (2024)

Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer
by: Yihua Huang, et al.
Published: (2024)

Beyond HER2 ‐Negative: Clinical and Molecular Relevance of HER2 ‐Ultralow Expression in Gynecologic Pathology
by: Gunvanti Rathod, et al.
Published: (2026)

Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status
by: Vitor Sousa
Published: (2015)

Características patológicas asociadas al carcinoma de mama HER-2 positivo
by: Carlos González-Müller
Published: (2005)

THE INFLUENCE OF GRANDMOTHERS ON BREASTFEEDING OF HER GRANDCHILDREN: BELIEFS AND CULTURAL PRACTICES
by: Leila Rangel da Silva
Published: (2013)

Interobserver Variability in HER‐2 Immunostaining Interpretation of Metastatic HER2 Low Breast Cancers in Cytology Specimens
by: Niyati Desai, et al.
Published: (2024)

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study
by: Jiahui Huang, et al.
Published: (2026)

The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti‐HER2 Antibodies and Immunotherapy
by: Panagiotis Sarantis, et al.
Published: (2026)

THE FACTORS OF THE WORK PROCESS OF THE NURSE THAT HINDER HER LIFE QUALITY
by: Letícia Carvalho Reis
Published: (2010)

Editorial for “Preoperative Differentiation of HER2‐Zero and HER2‐Low from HER2‐Positive Invasive Ductal Breast Cancers Using BI‐RADS MRI Features and Machine Learning Modeling”
by: Thais Maria S. Bezerra, et al.
Published: (2024)

Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
by: Mauricio Rodríguez
Published: (2023)

Evaluation of HER2/Neu gene in equivocal cases assessed by IHC in invasive breast cancer
by: Rafil Toma Yaqo
Published: (2021)

Transcriptional Reinforcement of the HER2 – RAS Network in HER2 ‐Positive Gastric Cancer: The RUNX – SOS1 Axis in Context
by: Tatsuya Masuda, et al.
Published: (2026)

FIBRO ODONTOMA AMELOBLÁSTICO ASOCIADO A CANINO INFERIOR DERECHO IMPACTADO
by: Ana Victoria Cordero-Loría
Published: (2015)

FACTORES PRONÓSTICOS Y PREDICTIVOS EN EL CÁNCER DE MAMA CON SOBRE-EXPRESIÓN DEL HER-2/NEU
by: MARÍA ANTONIETA RODRÍGUEZ GUERRA
Published: (2014)

CARACTERÍSTICAS MAMOGRÁFICAS DE LOS SUBTIPOS INTRÍNSECOS DE ALTO RIESGO TRIPLE NEGATIVO Y HER2
by: JOEL E RODRÍGUEZ
Published: (2014)

PDL1/HER2‐Targeted Lipid‐Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2+ Breast Cancer Immunotherapy
by: Jilai Tian, et al.
Published: (2024)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
by: Adriana Plata
Published: (2013)

An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
by: Jefferson Antonio Buendía
Published: (2013)

Toxicidad hepática en paciente con cáncer de mama metastático HER-2(+) en tratamiento con capecitabina y lapatinib
by: Elia Romero Carreño
Published: (2016)

Development of a deep‐learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2‐low cases
by: Pierre‐Antoine Bannier, et al.
Published: (2024)

HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti‐HER‐2/neu (4B5)
by: Yoshiya Horimoto, et al.
Published: (2024)

Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report
by: Patricia Miranda Romero
Published: (2015)

NICARAGUAN FEMINIST JOSEFA TOLEDO DE AGUERRI (1866-1962): HER LIFE AND HER LEGACY
by: Victoria González - Rivera
Published: (2005)

Improving HER2 Diagnostics with Digital Real‐Time PCR for Ultrafast, Precise Prediction of Anti‐HER2 Therapy Response in Patients with Breast Cancer
by: Hee‐Joo Choi, et al.
Published: (2025)

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2‐Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
by: Page E. Blas, et al.
Published: (2024)

HER 2/NEU UN ONCOGEN EN EL CÁNCER DE MAMA.
by: Gad Gamed Zavala Cruz
Published: (2007)

Insights Into the Emerging Entity of HER2‐Low Breast Cancer
by: Georges El Haddad, et al.
Published: (2024)

HER2‐positive grade 1 invasive carcinomas of the breast
by: Andrew H S Lee, et al.
Published: (2024)

HER2 mutation as an emerging target in advanced breast cancer
by: Giulia Bon, et al.
Published: (2024)